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were asked to complete Accept and MMAS-4 questionnaires at Month 1, 3 and 
6 after having given their informed consent. The structure was explored through 
PCA, and confirmed with multi-trait analysis. Internal consistency reliability 
of dimensions was assessed through Cronbach’s alpha. Scale-scale correla-
tions were calculated. Results: After reduction, Accept was made of 25 items 
organised in 1 overall Acceptance score and 6 domain-specific scores (efficacy, 
tolerance, convenience, constraints, treatment duration, multiple medica-
tion). Cronbach’s alpha was 0,85 for overall Acceptance score, which met con-
vergent and divergent validity criteria (both 100%). The domain-specific scores 
showed satisfactory to good results (Cronbach’s alpha ranging from 0,67 - 0,87, 
convegrent validity ranging from 63% to 100%, and divergent validity ranging 
from 33% - 100%). Scale-scale correlations ranged from 0.02 to 0.58, confirming the 
multi-dimensional nature of the questionnaire. The good properties of Accept were 
stable over time. ConClusions: Accept is a brief, comprehensive, generic ques-
tionnaire focused on Acceptance. Initial validation in a population of patients with 
a wide range of long-term treatment showed promising results and confirmed 
the position of Acceptance. Further, disease-specific, large prospective study are 
needed to assess the ability of Accept to predict persistence to treatment.
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objeCtives: Implementation of co-payments may reduce the use of essential medi-
cations, worsen patients’ outcomes, and increase overall health care costs. The aim 
of this study was to examine to what extent non-adherence of chronic patients to 
medication stems from financial reasons and what determinants are associated with 
non-adherence. Methods: A telephone survey was conducted among a representa-
tive sample of Maccabi Healthcare Services chronic patients aged ≥ 55 yrs (n= 522). 
Respondents were defined as non-adherent if they reported they had stopped tak-
ing prescribed medications in the previous year and/or not purchasing prescribed 
medications due to its cost. Additional information collected included: age, gender, 
income, receiving explanation from a physician regarding the therapy, and out-of-
pocket expenditure for prescribed medications. Results: Mean age of the study 
population was 69.9±9.0 yrs (53% were male). Sixteen percent of respondents were 
defined as non-adherent, in 60% of them it was due to medication’s cost. No sig-
nificant differences were found between adherent and non-adherent respondents 
with regard to: age, gender, family status, country of birth, supplementary insurance 
coverage, or education. In a multivariable logistic regression model, non-adherence 
was associated with: lack of physician explanation about prescribed medications 
(OR= 2.88, 95%CI: 1.46-5.68, P= 0.002); higher out-of-pocket expenditure on medications 
(OR= 1.93, 95%CI: 1.04-3.61, P= 0.04), and lower household income (OR= 0.81, 95%CI: 
0.69-0.96, P= 0.01). ConClusions: Information provided by physicians is associated 
with adherence of chronic patients to prescribed medications. Low income and high 
out-of-pocket expenditure for prescribed medication are associated with non-adher-
ence. Since adherence is strongly affected even by a relatively low and flat co-payment 
as applied in Maccabi Healthcare Services, health policy makers may consider adop-
tion of value-based co-payments that are differentiated by treatment value rather 
than by its cost, and targeted mainly at chronic patients. This approach may lead to 
improved adherence and outcomes with the potential of reducing long-term costs.
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objeCtives: In light of the presumed costs of non-adherence to medication and the 
pressure to reduce unnecessary health care expenditures in the current economic 
climate, a review that assesses evidence of cost-effectiveness of adherence enhancing 
interventions would be timely. The objective of this paper is to examine the cost-
effectiveness of adherence enhancing interventions and the quality of the studies 
reviewed. Methods: MEDLINE, PsycInfo, EconLit and the Centre for Reviews and 
Dissemination databases were searched for randomised controlled trials that per-
formed full economic evaluations of adherence enhancing interventions. Information 
was collected on study characteristics, cost-effectiveness of treatment alternatives, 
quality of economic evaluations, and risk of bias. Results: Fourteen studies were 
included, of which the overall quality was found to be moderate. Five used a societal 
perspective, eight a provider perspective, and a single study used a patient perspec-
tive. Ten studies examined interventions that were both more costly and more effec-
tive than usual care, and four were less costly and more effective. Comprehensive 
evidence from the societal perspective yielded disappointing results for potential 
cost-effectiveness of adherence interventions. Studies from other perspectives pro-
vided weak to moderately promising evidence that adherence interventions can 
be cost-effective. ConClusions: Few randomised controlled trials examined the 
cost-effectiveness of adherence interventions. There was limited evidence of poten-
tial cost-effectiveness of adherence programmes. Most interventions did not report 
whether their intervention was effective in the first place, and many suffered from 
methodological limitations. To demonstrate that adherence interventions offer soci-
etal benefits, we recommend that the most promising interventions are subjected to 
a rigorous cost-effectiveness evaluation.
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and 97.87% respectively. ConClusions: This analysis portends dienogest as a cost-
saving alternative for the treatment of EAPP compared to GnRHa in Brazil from the 
public and private payer perspective.
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objeCtives: In England, nearly two-thirds of older people in acute hospital care 
suffer from co-morbid physical and mental health conditions. This study inves-
tigated the health and social care costs for a group of older (70+) people iden-
tified with a mental health condition after hospital admission. Methods: The 
Better Mental Health (BMH) study recruited 247 patients at hospital admission in 
Nottingham, England. Electronic administrative records were sought for six months 
post-admission from health (services: general practices, hospitals, ambulance trans-
port, intermediate and mental health care) and social care. The cohort was charac-
terised by one or more aspects of mental health: cognitive impairment, depression, 
delirium, and neuropsychiatric health. Differences in mean cost between groups 
were assessed using t-tests; association between mental health and service-level 
cost was investigated using GLM regression. Results: Health and social care costs 
were derived for all 247 participants, except primary care, derived for 122 (subset) 
participants due to GP recruitment. In the subset, mean (95% CI, median, range) total 
cost was £9842 (8573-11256, 7717, 715-48795). Mean cost (95% CI) for mental health 
care was significantly (p< 0.05) higher for patients: with depression than without 
(£194 (106-322) Vs. £55 (17-111)); bottom-50% on the neuropsychiatric health scale 
(£202 (124-298) Vs. £55 (16-118)). Patients with delirium, compared to without, had 
significantly lower costs for GP consultations (£316 (196-492) Vs. £552 (429-701)) 
and hospital outpatient visits (£333 (253-444) Vs. £497 (400-621)). The GLM did not 
identify a significant association between aspects of mental health and service-
level costs. ConClusions: This study suggests a person’s mental health affects 
consumption of some, but not all, services evaluated. In general, these patients are 
costly, high resource-users, of health and social care services; however, this con-
sumption pattern cannot be attributed to one particular aspect of mental health. 
Future work should investigate the impact of physical and mental health comor-
bidities on resource-use.
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objeCtives: To determine the association between medication adherence and 
adverse drug events (ADEs), health related quality of life (HRQOL) and hospitalisa-
tion in older community dwelling patients. Methods: A retrospective cohort study 
of 855 patients aged ≥ 70 years from 15 general practices in Ireland in 2010. Medication 
adherence was measured by: (i) the Medication Possession Ratio (MPR) using national 
pharmacy claims dispensing data; and (ii) self-report using the Morisky Medication 
Adherence Scale. ADEs and hospitalisation were measured by patient medical record 
and self-report for the previous 6 months. ADEs were reviewed by two independent 
clinicians. HRQOL was measured using EQ-5D. Multilevel Poisson and linear regression 
were used to examine how the number of ADEs, utility and hospitalisation varied by 
adherence after adjusting for patient and practice level covariates; socioeconomic 
status, deprivation, co-morbidity, number of drugs, functional disabilities, social sup-
port and health insurance. Results: A total of 592 (69%) patients were adherent 
based on dispensed pharmacy claims data (MPR ≥ 80%) and 553 (63%) self-reported 
adherence to their medication. The median MPR for self-reported adherent patients 
was 0.88 (IQR: 0.78, 0.95) compared to 0.86 (IQR: 0.71, 0.93) for non-adherent patients 
(p< 0.01). Non-adherence (MPR< 80%) was not significantly associated with any ADEs 
but self-reported non-adherent patients had an increased risk of any ADEs (IRR 1.18; 
95% CI 1.05, 0, 1.33 p< 0.01). Non-adherent patients had a significantly lower mean 
HRQOL utility (MPR coefficient, -0.11, SE 0.03, p< 0.001; self-report coefficient, -0.06, 
SE 0.01, p< 0.001) and an almost two-fold increased risk in the expected rate of any 
hospitalisation (MPR IRR, 1.75; 95% CI, 1.42, 2.15, p< 0.001; self-report IRR, 1.53; 95% CI, 
1.16, 2.01, p< 0.01) compared to adherent patients. ConClusions: Non-adherence 
was significantly associated with adverse health outcomes. Developing methods 
to assist older adults in accurate and safe management of their medications may 
increase their quality of life.
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objeCtives: To reduce, score, and validate the Accept questionnaire. Methods: 
Accept is a 32-items PRO questionnaire measuring the concept of Acceptance. 
It was developed based on grounded theory and qualitative research. Each 
treatment characteristic was assessed on a response scale opposing “easy to 
accept” to “not easy to accept”. We conducted an observational prospective 
study on 182 subjects engaged in long-term treatment regimen. Adult patients 
where consecutively recruited by a network of pharmacists when prescribed 
with a drug indicated in various chronic diseases (including asthma, diabetes, 
various cardio-vascular diseases, retroviral infections, osteoporosis). Patients 
